ChemGenex's Omapro Faces Scaled Back Efficacy Claims After Trial Shortcomings
Briefing documents for the advisory committee, now delayed by snow, show that many enrollees lacked a confirmed Bcr-Abl T315I mutation.
Briefing documents for the advisory committee, now delayed by snow, show that many enrollees lacked a confirmed Bcr-Abl T315I mutation.